Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide in antipsychotic-associated diabetes in schizophrenia
NL-OMON40321Phase 4Withdrawn
- Sponsor
- Interne geneeskunde
- Start
- Sep 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) comparing Liraglutide with Placebo (2 arms). Primary endpoint: Change in HbA1c. Planned start Sep 2014; status: withdrawn.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON40321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40321.